Monthly Archives: February 2016

Biothera Announces Publication of Imprime PGG Positive Safety Findings and Pharmacokinetic Data from Two Phase 1 Studies

Results published in Investigational New Drugs: The Journal of New Anticancer Agents Imprime PGG (Beta 1,3/1,6 glucan) also has established proof of concept as an immuno-oncology therapy in subsequent single arm and randomized Phase 2 studies With significant milestones anticipated throughout 2016, Biothera is advancing Imprime PGG towards registration trials by 2018 EAGAN, MN — February 25, 2016 — Biothera Pharmaceuticals Inc. today announced the peer-reviewed...

Read More

Biothera Pharmaceuticals Inc. to Present at the 18th Annual BIO CEO & Investor Conference

EAGAN, MN — February 2, 2016 — Biothera Pharmaceuticals Inc. announced today that Barry Labinger, Chief Executive Officer, will present at the 18th Annual BIO CEO & Investor Conference on Tuesday, February 9, 2016 at 10:00a.m. Eastern Time in New York, NY. Mr. Labinger will provide an overview of Biothera and business update. Biothera Pharmaceuticals Inc. was selected as the winner of the “Most Buzzworthy...

Read More